Combination Chemotherapy Increases Cytotoxicity of Multiple Myeloma Cells by Modification of Nuclear Factor (NF)-κB Activity

Experimental Hematology - Netherlands
doi 10.1016/j.exphem.2012.10.002
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Fas-Associated Factor-1 Inhibits Nuclear Factor-κB (NF-κB) Activity by Interfering With Nuclear Translocation of the RelA (P65) Subunit of NF-κB

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2003English

Retraction: Modification of Cysteine Residue in P65 Subunit of Nuclear Factor-κB (NF-κB) by Picroliv Suppresses NF-κB–Regulated Gene Products and Potentiates Apoptosis

Cancer Research
Cancer ResearchOncology
2018English

Ibrutinib Targets microRNA-21 in Multiple Myeloma Cells by Inhibiting NF-κB and STAT3

Tumor Biology
MedicineCancer Research
2018English

Regulation of the Nuclear Factor (NF)-κB Pathway by ISGylation

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2008English

Regulation of STAT3 and NF-κB Activations by S-Nitrosylation in Multiple Myeloma

Free Radical Biology and Medicine
BiochemistryPhysiology
2017English

Loss of NF-κB Activity During Cerebral Ischemia and TNF Cytotoxicity

Molecular Medicine
Molecular MedicineGeneticsMolecular Biology
1999English

Inhibition of Hepatocyte Nuclear Factor 4 Transcriptional Activity by the Nuclear Factor κB Pathway

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2006English

TDP-43 Inhibits NF-κB Activity by Blocking P65 Nuclear Translocation

PLoS ONE
Multidisciplinary
2015English

VCAP Combination Chemotherapy for Multiple Myeloma in the Aged.

Japanese Journal of Geriatrics
GerontologyGeriatrics
1991English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy